NO135788B - - Google Patents
Download PDFInfo
- Publication number
- NO135788B NO135788B NO1507/72A NO150772A NO135788B NO 135788 B NO135788 B NO 135788B NO 1507/72 A NO1507/72 A NO 1507/72A NO 150772 A NO150772 A NO 150772A NO 135788 B NO135788 B NO 135788B
- Authority
- NO
- Norway
- Prior art keywords
- compound
- formula
- fibrinolytic
- dose
- test
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- WZBZLXHSUKNNEF-UHFFFAOYSA-N 2-propan-2-yl-1-benzofuran Chemical compound C1=CC=C2OC(C(C)C)=CC2=C1 WZBZLXHSUKNNEF-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 150000001907 coumarones Chemical class 0.000 claims description 5
- 239000012458 free base Substances 0.000 claims description 5
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 claims description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 20
- 230000003480 fibrinolytic effect Effects 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000003527 fibrinolytic agent Substances 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012429 reaction media Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000005686 Serum Globulins Human genes 0.000 description 3
- 108010045362 Serum Globulins Proteins 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009424 thromboembolic effect Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- ILXDAXZQNSOSAE-UHFFFAOYSA-N [AlH3].[Cl] Chemical compound [AlH3].[Cl] ILXDAXZQNSOSAE-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- BNTRVUUJBGBGLZ-UHFFFAOYSA-N hydron;pyridine-4-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=NC=C1 BNTRVUUJBGBGLZ-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229960003868 paraldehyde Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- PVXCGWNPDFFPOV-UHFFFAOYSA-M sodium;pyridine-4-carboxylate Chemical compound [Na+].[O-]C(=O)C1=CC=NC=C1 PVXCGWNPDFFPOV-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000014754 thrombocytosis disease Diseases 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1227771 | 1971-04-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO135788B true NO135788B (fr) | 1977-02-21 |
| NO135788C NO135788C (fr) | 1977-06-01 |
Family
ID=10001598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1507/72A NO135788C (fr) | 1971-04-29 | 1972-04-28 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US3810991A (fr) |
| AR (1) | AR192932A1 (fr) |
| AT (1) | AT319243B (fr) |
| AU (1) | AU456733B2 (fr) |
| BE (1) | BE782604A (fr) |
| CA (1) | CA971481A (fr) |
| CH (1) | CH540930A (fr) |
| DE (1) | DE2220361A1 (fr) |
| DK (1) | DK139871B (fr) |
| ES (1) | ES402285A1 (fr) |
| FR (1) | FR2134435B1 (fr) |
| GB (1) | GB1335403A (fr) |
| IE (1) | IE36278B1 (fr) |
| NL (1) | NL7205784A (fr) |
| NO (1) | NO135788C (fr) |
| OA (1) | OA04005A (fr) |
| SE (1) | SE392104B (fr) |
| ZA (1) | ZA722478B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806663A (en) * | 1987-04-06 | 1989-02-21 | The University Of Tennessee Research Corporation | Certain 3-substituted 2-alkyl benzofuran derivatives |
| US4851554A (en) * | 1987-04-06 | 1989-07-25 | University Of Tennessee Research Corporation | Certain 3-substituted 2-alkyl benzofuran derivatives |
| US4831156A (en) * | 1987-09-30 | 1989-05-16 | The University Of Tennessee Research Corp. | 3-substituted 2-alkyl indole derivatives |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL136620C (fr) * | 1963-04-30 | |||
| GB1245283A (en) * | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
-
1971
- 1971-04-29 GB GB1227771A patent/GB1335403A/en not_active Expired
-
1972
- 1972-04-11 IE IE473/72A patent/IE36278B1/xx unknown
- 1972-04-13 ZA ZA722478A patent/ZA722478B/xx unknown
- 1972-04-17 US US00244495A patent/US3810991A/en not_active Expired - Lifetime
- 1972-04-19 AU AU41318/72A patent/AU456733B2/en not_active Expired
- 1972-04-20 AR AR241576A patent/AR192932A1/es active
- 1972-04-24 FR FR7214422A patent/FR2134435B1/fr not_active Expired
- 1972-04-25 BE BE782604A patent/BE782604A/fr unknown
- 1972-04-26 CH CH618172A patent/CH540930A/fr not_active IP Right Cessation
- 1972-04-26 DE DE19722220361 patent/DE2220361A1/de active Pending
- 1972-04-27 DK DK210272AA patent/DK139871B/da unknown
- 1972-04-28 NO NO1507/72A patent/NO135788C/no unknown
- 1972-04-28 NL NL7205784A patent/NL7205784A/xx not_active Application Discontinuation
- 1972-04-28 SE SE7205672A patent/SE392104B/xx unknown
- 1972-04-28 OA OA54553A patent/OA04005A/fr unknown
- 1972-04-28 AT AT373872A patent/AT319243B/de not_active IP Right Cessation
- 1972-04-28 CA CA141,147A patent/CA971481A/en not_active Expired
- 1972-04-29 ES ES402285A patent/ES402285A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU4131872A (en) | 1973-10-25 |
| DK139871C (fr) | 1979-10-08 |
| SE392104B (sv) | 1977-03-14 |
| ZA722478B (en) | 1972-12-27 |
| ES402285A1 (es) | 1975-03-16 |
| AU456733B2 (en) | 1974-12-06 |
| NL7205784A (fr) | 1972-10-31 |
| OA04005A (fr) | 1979-09-15 |
| CH540930A (fr) | 1973-08-31 |
| NO135788C (fr) | 1977-06-01 |
| DE2220361A1 (de) | 1972-11-02 |
| BE782604A (fr) | 1972-10-25 |
| FR2134435A1 (fr) | 1972-12-08 |
| IE36278B1 (en) | 1976-09-29 |
| GB1335403A (en) | 1973-10-31 |
| DK139871B (da) | 1979-05-07 |
| US3810991A (en) | 1974-05-14 |
| AT319243B (de) | 1974-12-10 |
| AR192932A1 (es) | 1973-03-21 |
| IE36278L (en) | 1972-10-29 |
| FR2134435B1 (fr) | 1976-04-16 |
| CA971481A (en) | 1975-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK159770B (da) | Analogifremgangsmaade til fremstilling af etherforbindelser eller farmakologisk acceptable salte deraf, samt ether-mellemprodukter til anvendelse som udgangsforbindelser ved fremgangsmaaden | |
| NO165924B (no) | Analogifremgangsmaate for fremstilling av den terapeutisk aktive hoeyredreiende enantiomer av metyl-alfa 5(4,5,6,7-tetrahydro (3,2-c)-tieno-pyridyl)-(2-klorfenyl)-acetat. | |
| NO140424B (no) | Analogifremgangsmaate for fremstilling av farmakologisk aktive indolderivater | |
| CS226182B2 (en) | Method of preparing 1-(p-methoxybenzoyl)-2-pyrrolidinone | |
| PL106415B1 (pl) | Sposob wytwarzania nowych pochodnych poli/h-/siarczanu poligalaktozydosacharozy | |
| US3622615A (en) | N{11 -(p-tolylsulfonyl)-L-arginine esters | |
| TIPSON et al. | The Action of Sodium Iodide on Some Esters of P-Toluenesulfonic Acid1 | |
| US3371014A (en) | Method of combating angina pectoris and a pharmaceutical preparation suitable for this purpose | |
| US4096252A (en) | 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents | |
| NO135788B (fr) | ||
| Dalla Via et al. | An eudesman derivative from Verbesina persicifolia DC as a natural mild uncoupler in liver mitochondria. A new potential anti-obesity agent? | |
| WO2008008273A1 (fr) | Forme polymorphe du fluoro-7-(2,2,2-trifluoroéthoxy) phénoxathiine-10,10-dioxyde | |
| NO780040L (no) | Fremgangsmaate ved fremstilling av nye piperidinderivater | |
| US3164517A (en) | Process of effecting diuresis with lower alkyl disulfamylaniline compounds | |
| NO760116L (fr) | ||
| US7601838B2 (en) | 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents | |
| KR102209441B1 (ko) | 혈소판 응집 저해 효과를 갖는 화합물 및 그 염, 그리고 이를 포함하는 혈전성 질환 예방 또는 치료용 조성물 | |
| NO117505B (fr) | ||
| US4055648A (en) | Papaverine thienyl-carboxylates and medicaments containing them | |
| US2810743A (en) | 2-ammonio-ethyl 3-ammoniopropionates | |
| Nicolaides et al. | Synthetic bradykinin analogs | |
| CN108912142B (zh) | 吡咯并苯并恶嗪酮类化合物及其注射剂和在抗血栓中的用途 | |
| NO125182B (fr) | ||
| Chapman et al. | 197. Studies of the Beckmann change. Part I. The spontaneous rearrangement of oxime picryl ethers | |
| US3284297A (en) | 2-n-methylammoniumethylthiosulfuric acid and its use as a radioprotective agent |